CD147 Aggravated Inflammatory Bowel Disease by Triggering NF-κB-Mediated Pyroptosis. (2nd July 2020)

• Record Type: Journal Article
• Authors: Xu, Zhaohui; Liu, Ruitao; Huang, Ling; Xu, Yuxin; Su, Mingmin; Chen, Jiayu; Geng, Lanlan; Xu, Wanfu; Gong, Sitang
• Other Names: Chiba Toshimi Academic Editor.
• Is Part Of: BioMed research international. Volume 2020(2020)
• Publication Date: 2020-07-02
• Subjects: Medicine -- Periodicals; Biology -- Periodicals; Biotechnology -- Periodicals; Life sciences -- Periodicals; 610.5
• DOI: 10.1155/2020/5341247
• Languages: English
• ISSNs: 2314-6133

Abstract

Abstract : Background . Pyroptosis, a novel form of inflammatory programmed cell death, was recently found to be a cause of mucosal barrier defect. In our pervious study, CD147 expression was documented to increase in intestinal tissue of inflammatory bowel disease (IBD). Objective . The aim of this study was to determine the function of serum CD147 in pyroptosis. Methods . The study group consisted of 96 cases. The centration of CD147, IL-1 β, and IL-18 levels in serum was assessed by ELISA. Real-time PCR and WB were performed to analyze the effect of CD147 on pyroptosis. Results . In this study, our results showed that CD147 induced cell pyroptosis in intestinal epithelial cells (IECs) by enhancement of IL-1 β and IL-18 expression and secretion in IECs, which is attributed to activation of inflammasomes, including caspase-1 and GSDMD as well as GSDME, leading to aggregate inflammatory reaction. Mechanically, CD147 promoted phosphorylation of NF- κ B p65 in IECs, while inhibition of NF- κ B activity by the NF- κ B inhibitor BAY11-7082 reversed the effect of CD147 on IL-1 β and IL-18 secretion. Most importantly, serum CD147 level is slightly clinically correlated with IL-1 β, but not IL-18 level. Conclusion . These findings revealed a critical role of CD147 in the patients with IBD, suggesting that blockade of CD147 may be a novel therapeutic strategy for the patients with IBD.